Amgen Inc Investor Call At IASLC 2019 World Conference on Lung Cancer Transcript
My name is Mary, and I will be your conference facilitator today for Amgen's call in conjunction with the World Conference on Lung Cancer. (Operator Instructions)
I would now like to introduce Arvind Sood, Vice President of Investor Relations. Mr. Sood, you may now begin.
Thank you, Mary. So first, I would like to welcome all of you to our call this morning. For those in the United States, good morning; and for those in Barcelona, I wish I was there with you.
So we presented new clinical data today at the ongoing World Conference on Lung Cancer. This data is from our ongoing Phase I study evaluating AMG 510 in patients with previously treated KRAS G12C-mutated solid tumors. I'm joined this morning by our Head of R&D, Dr. David Reese, who will briefly highlight the breadth of our oncology portfolio and development; followed by Dr. Greg Friberg, who's our Vice President of Global Oncology Development. Greg will review the data on AMG 510 that was presented today in the scientific session. After Greg's
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |